A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention
NCT02630459
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
475
Enrollment
INDUSTRY
Sponsor class
Conditions
Migraine
Interventions
DRUG:
Placebo
DRUG:
Erenumab
DRUG:
Erenumab
Sponsor
Amgen